Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.

Abstract: Magnetically responsive particles can include two or more magnetically responsive layers (“MRL”). As such, the particles can have the following: a polymeric core; a first magnetically responsive layer (“MRL”) on the core; a first polymeric layer bound to the first MRL; a second MRL layer bound to the first polymeric layer; and a second polymeric layer bound to the second MRL. The particles can have a faster magnetic response time compared to a similar particle having only a single MRL, which can be at least 25% faster. Also, the particle can have a magnetic squareness of less than about 0.1. Preferably, the particle can have negligible residual magnetism after being exposed to a magnetic field sufficient for the particle to respond thereto. Further, the particle can be colloidally stable in water at concentrations from about 0.1 to 10 grams of particle per 100 milliliters of water.

Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.

Abstract: Topiramate analogs have substituents at the sulfamate group, 9-position, or 10-position. Topiramate analogs may include immunogenic moieties to prepare anti-topiramate antibodies, or antigenic moieties for immunodiagnostic assays. Also, the topiramate analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the topiramate analogs can be used in immunodiagnostic assays to compete with topiramate for binding with anti-topiramate antibodies. Such an immunodiagnostic assay can be used for detecting the presence of topiramate in a sample obtained from a subject previously administered topiramate by the following: combining an anti-topiramate antibody and a topiramate analog with a sample to form a first composition; allowing any free topiramate from the sample and the topiramate analog to compete for binding with the antibody; detecting binding between the topiramate analog and the antibody.

Abstract: Generally, the present invention relates to topiramate analogs that have substituents at the sulfamate group or at the 9-position or 10-position. The topiramate analogs can include immunogenic moieties that can be used to prepare anti-topiramate antibodies, or antigenic moieties that can be used in immunodiagnostic assays for topiramate. Also, the topiramate analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the topiramate analogs can be used in immunodiagnostic assays to compete with topiramate for binding with anti-topiramate antibodies.

Abstract: Topiramate analogs have substituents at the sulfamate group, 9-position, or 10-position. Topiramate analogs may include immunogenic moieties to prepare anti-topiramate antibodies, or antigenic moieties for immunodiagnostic assays. Also, the topiramate analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the topiramate analogs can be used in immunodiagnostic assays to compete with topiramate for binding with anti-topiramate antibodies. Such an immunodiagnostic assay can be used for detecting the presence of topiramate in a sample obtained from a subject previously administered topiramate by the following: combining an anti-topiramate antibody and a topiramate analog with a sample to form a first composition; allowing any free topiramate from the sample and the topiramate analog to compete for binding with the antibody; detecting binding between the topiramate analog and the antibody.

Abstract: Magnetically responsive microparticles and a method for their production are described. Oppositely charged core particles and magnetite are heterocoagulated, redispersed and optionally coated. The microparticles are colloidally stable and have negligible retentivity.Having now fully described the invention, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein.

Abstract: An improved, copolymer-based immunoassay system, method, and apparatus is highly sensitive and effective in accurately measuring extremely low concentrations, such as 10.sup.-6 to 10.sup.-12 grams per milliliter, of biologically active substances, such as monoclonal or polyclonal antibodies and antigens, cancer markers, proteins, bacteria, viruses, therapeutic drugs, drugs of abuse, and food and water contaminants in fluid samples. The system requires no sample preparation, and is reliable, easy to use, sufficiently low in cost to be readily usable in doctors' offices, small labs, and other low-volume facilities, but is also readily adaptable to hospital and high-volume use. The new system, method, and apparatus for agglutination immunoassay systems includes novel and coordinated carrier particle technology, light application and measurement and chemistry, coacting to provide the multiple advantages of simplicity and accuracy in use, and extreme sensitivity in application, in quantifying immunoassays.